68Ga-NEB
( DrugBank: - / KEGG DRUG: - )
4 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 46 | Malignant rheumatoid arthritis | 1 |
| 89 | Lymphangioleiomyomatosis | 1 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 278 | Huge lymphatic malformation with cervicofacial lesion | 1 |
| 280 | Huge arteriovenous malformation with cervicofacial or limb lesion | 1 |
46. Malignant rheumatoid arthritis
Clinical trials : 4,743 / Drugs : 3,042 - (DrugBank : 389) / Drug target genes : 205 - Drug target pathways : 253
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
89. Lymphangioleiomyomatosis
Clinical trials : 44 / Drugs : 54 - (DrugBank : 19) / Drug target genes : 27 - Drug target pathways : 143
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
278. Huge lymphatic malformation with cervicofacial lesion
Clinical trials : 47 / Drugs : 48 - (DrugBank : 15) / Drug target genes : 8 - Drug target pathways : 142
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
280. Huge arteriovenous malformation with cervicofacial or limb lesion
Clinical trials : 36 / Drugs : 41 - (DrugBank : 17) / Drug target genes : 12 - Drug target pathways : 169
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
